Claims for Patent: 9,750,747

Summary for Patent: 9,750,747

Title:	Treatments involving eslicarbazepine acetate or eslicarbazepine
Abstract:	The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.
Inventor(s):	Soares Da Silva; Patricio Manuel Vieira Araujo (Sao Mamede do Coronado, PT)
Assignee:	BAIL-PORTELA & CA, S.A. (Sao Mamede do Coronado, PT)
Application Number:	14/240,847
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,750,747
Patent Claims:	1. A method of treating partial-onset seizures in a patient who is suffering from or susceptible to absence seizures, which method comprises: administering to said patient a safe and effective amount of eslicarbazepine acetate. 2. The method according to claim 1, wherein the patient is female. 3. The method according to claim 1, wherein the patient is under sixteen years of age. 4. The method according to claim 1, wherein the patient has not reached puberty. 5. The method according to claim 1, wherein the patient has previously suffered from at least one seizure selected from the group consisting of absence seizure, myoclonic seizure and tonic-clonic seizure. 6. The method according to claim 1, wherein the patient has a family history of epilepsy. 7. The method according to claim 1, wherein the patient has the R43Q mutation in the .gamma.-aminobutyric acid (GABA).sub.A receptor .gamma.-2 subunit. 8. The method according to claim 1, wherein the patient is suffering from or susceptible to at least one disease or syndrome selected from the group consisting of: childhood absence epilepsy, juvenile absence epilepsy, myoclonic absence epilepsy, juvenile myoclonic epilepsy, Lennox Gastaut syndrome, perioral myoclonus with absences, Jeavons syndrome and idiopathic generalized epilepsy with phantom absences. 9. The method according to claim 1, wherein the patient is receiving a second drug which may cause or aggravate absence seizures. 10. The method according to claim 9, wherein the second drug is selected from the group consisting of: carbamazepine, oxcarbazepine, vigabatrin, tiagabine, phenytoin, phenobarbital, gabapentin, and pregabalin. 11. The method according to claim 1, wherein the eslicarbazepine acetate is administered orally. 12. The method according to claim 1, wherein the eslicarbazepine acetate is administered once daily. 13. The method according to claim 1, wherein the patient receives one or more additional medications for treatment of partial-onset seizures. 14. The method according to claim 13, wherein the additional medication is selected from the group consisting of: clorazepate, clonazepam, ethosuximide, felbamate, fosphenytoin, lacosamide, lamotrigine, levetiracetam, primidone, topiramate, valproate semisodium, valproic acid, and zonisamide. 15. The method according to claim 1, wherein the eslicarbazepine acetate is administered to the patient as an adjunct therapy. 16. A method of treating partial-onset seizures in a patient who is suffering from or susceptible to absence seizures, which method comprises: administering to said patient a safe and effective amount of a pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a safe and effective amount of eslicarbazepine acetate as an active ingredient. 17. The method according to claim 16, wherein the pharmaceutical composition is in the form of a tablet, a suspension or a sprinkle formulation. 18. A method of treating partial onset seizures, which method comprises: (a) selecting a patient who is suffering from or susceptible to absence seizures; and (b) administering to said patient a safe and effective amount of eslicarbazepine acetate, or a pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a safe and effective amount of eslicarbazepine acetate as an active ingredient. 19. A method of reducing the incidence of absence seizures in a patient, which method comprises administering to said patient a safe and effective amount of eslicarbazepine acetate, or a pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a safe and effective amount of eslicarbazepine acetate as an active ingredient.